Loading...
Header Logo
Keywords
Last Name
Institution

ISABELLE BEDROSIAN

TitleProfessor
InstitutionMD Anderson
DepartmentBreast Surgical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Buszek SM, Lin HY, Bedrosian I, Tamirisa N, Babiera GV, Shen Y, Shaitelman SF. Lumpectomy plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older with Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database. Int J Radiat Oncol Biol Phys. 2019 Aug 01. PMID: 31377160.
      View in: PubMed
    2. Wood ME, Garber JE, Isaacs C, Masood S, Bedrosian I, Tung N, Chun J, Schnabel FR, Arun BK. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. Breast J. 2019 07; 25(4):575-577. PMID: 31280501.
      View in: PubMed
    3. Carter S, Neuman H, Mamounas EP, Bedrosian I, Moulder S, Montero AJ, Jagsi R. Debating the Optimal Approach to Nodal Management After Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:42-48. PMID: 31099648.
      View in: PubMed
    4. Weiss A, Lin H, Babiera GV, Bedrosian I, Shaitelman SF, Shen Y, Kuerer HM, Mittendorf EA, Caudle AS, Hunt KK, Hwang RF. Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes. Breast Cancer Res Treat. 2019 Jul; 176(2):435-444. PMID: 31025270.
      View in: PubMed
    5. Wood ME, Cuke M, Bedrosian I. Prevention Therapy for Breast Cancer: How Can We Do Better? Ann Surg Oncol. 2019 Jul; 26(7):1970-1972. PMID: 30798445.
      View in: PubMed
    6. Park KU, Kyrish K, Terrell J, Yi M, Caudle AS, Hunt KK, Kuerer HM, Bedrosian I, Thompson A, DeSnyder SM. Surgeon perception versus reality: Opioid use after breast cancer surgery. J Surg Oncol. 2019 Jun; 119(7):909-915. PMID: 30737785.
      View in: PubMed
    7. Bedrosian I, Parker PA, Brewster AM. Who should get a contralateral prophylactic mastectomy for breast cancer? Cancer. 2019 May 01; 125(9):1400-1403. PMID: 30645775.
      View in: PubMed
    8. D'Agostino TA, Brewster AM, Peterson SK, Bedrosian I, Parker PA. Discussions about contralateral prophylactic mastectomy among surgical oncology providers and women with sporadic breast cancer: a content analysis. Transl Behav Med. 2018 Dec 18. PMID: 30561744.
      View in: PubMed
    9. DeSnyder SM, Kheirkhah P, Travis ML, Lilly SE, Bedrosian I, Buchholz TA, Schaverien MV, Shaitelman SF. Optimizing Patient Positioning to Reduce Variation in the Measurement of Breast Cancer-Related Lymphedema. Lymphat Res Biol. 2019 Aug; 17(4):440-446. PMID: 30562149.
      View in: PubMed
    10. Bhardwaj A, Singh H, Trinidad CM, Albarracin CT, Hunt KK, Bedrosian I. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Breast Cancer Res. 2018 12 11; 20(1):150. PMID: 30537987.
      View in: PubMed
    11. Stecklein SR, Shaitelman SF, Babiera GV, Bedrosian I, Black DM, Ballo MT, Arzu I, Strom EA, Reed VK, Dvorak T, Smith BD, Woodward WA, Hoffman KE, Schlembach PJ, Kirsner SM, Nelson CL, Yang J, Guerra W, Dibaj S, Bloom ES. Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation With Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy. Pract Radiat Oncol. 2019 Jan; 9(1):e4-e13. PMID: 30125673.
      View in: PubMed
    12. Weiss A, Chu CK, Lin H, Shen Y, Shaitelman SF, Garvey PB, Bedrosian I, Babiera GV. Reconstruction in the Metastatic Breast Cancer Patient: Results from the National Cancer Database. Ann Surg Oncol. 2018 Oct; 25(11):3125-3133. PMID: 30109538.
      View in: PubMed
    13. Parker PA, Peterson SK, Shen Y, Bedrosian I, Black DM, Thompson AM, Nelson JC, DeSnyder SM, Cook RL, Hunt KK, Volk RJ, Cantor SB, Dong W, Brewster AM. Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer. J Clin Oncol. 2018 Sep 01; 36(25):2630-2638. PMID: 30044695.
      View in: PubMed
    14. Bedrosian I. Screening Mammography: Getting to Version 2.0. Ann Surg Oncol. 2018 Sep; 25(9):2500-2501. PMID: 29796872.
      View in: PubMed
    15. Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK, Bedrosian I, Arun BK. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med. 2018 06; 7(6):2718-2726. PMID: 29733510.
      View in: PubMed
    16. Raber B, Bea VJ, Bedrosian I. How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Surgical Oncologist. Magn Reson Imaging Clin N Am. 2018 May; 26(2):281-288. PMID: 29622133.
      View in: PubMed
    17. Weiss A, Menen RS, Lin HY, Shen Y, Rosso KJ, Shaitelman S, Woodward W, Valero V, Ueno NT, Bedrosian I, Babiera G. Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. Breast Cancer Res Treat. 2018 Jun; 169(3):615-623. PMID: 29460033.
      View in: PubMed
    18. Yao K, Belkora J, Bedrosian I, Rosenberg S, Sisco M, Barrera E, Kyrillos A, Tilburt J, Wang C, Rabbitt S, Pesce C, Simovic S, Winchester DJ, Sepucha K. Erratum to: Impact of an In-visit Decision Aid on Patient Knowledge about Contralateral Prophylactic Mastectomy: A Pilot Study. Ann Surg Oncol. 2017 12; 24(Suppl 3):687. PMID: 28349337.
      View in: PubMed
    19. Weiss A, Mittendorf EA, DeSnyder SM, Hwang RF, Bea V, Bedrosian I, Hoffman K, Adrade B, Sahin AA, Kuerer HM, Hunt KK, Caudle AS. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. Clin Breast Cancer. 2018 08; 18(4):276-281. PMID: 29100726.
      View in: PubMed
    20. Caudle AS, Bedrosian I, Milton DR, DeSnyder SM, Kuerer HM, Hunt KK, Mittendorf EA. Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. Ann Surg Oncol. 2017 Oct; 24(10):2925-2934. PMID: 28766207.
      View in: PubMed
    21. Akay CL, Albarracin C, Torstenson T, Bassett R, Mittendorf EA, Yi M, Kuerer HM, Babiera GV, Bedrosian I, Hunt KK, Hwang RF. Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J. 2018 01; 24(1):28-34. PMID: 28608612.
      View in: PubMed
    22. Moreno AC, Lin YH, Bedrosian I, Shen Y, Stauder MC, Smith BD, Buchholz TA, Babiera GV, Woodward WA, Shaitelman SF. Use of regional nodal irradiation and its association with survival for women with high-risk, early stage breast cancer: A National Cancer Database analysis. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):291-300. PMID: 29114595.
      View in: PubMed
    23. Bhardwaj A, Singh H, Rajapakshe K, Tachibana K, Ganesan N, Pan Y, Gunaratne PH, Coarfa C, Bedrosian I. Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer. Oncotarget. 2017 Mar 21; 8(12):19645-19660. PMID: 28160548.
      View in: PubMed
    24. Lin HY, Bedrosian I, Babiera GV, Shaitelman SF, Kuerer HM, Woodward WA, Ueno NT, Shen Y. Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer. 2017 Jul 15; 123(14):2618-2625. PMID: 28295213.
      View in: PubMed
    25. Mitchell KB, Lin H, Shen Y, Colfry A, Kuerer H, Shaitelman SF, Babiera GV, Bedrosian I. DCIS and axillary nodal evaluation: compliance with national guidelines. BMC Surg. 2017 Feb 07; 17(1):12. PMID: 28173790.
      View in: PubMed
    26. Raghavendra A, Sinha AK, Le-Petross HT, Garg N, Hsu L, Patangan M, Bevers TB, Shen Y, Banu A, Tripathy D, Bedrosian I, Barcenas CH. Mammographic breast density is associated with the development of contralateral breast cancer. Cancer. 2017 06 01; 123(11):1935-1940. PMID: 28135395.
      View in: PubMed
    27. FitzSullivan E, Bassett RL, Kuerer HM, Mittendorf EA, Yi M, Hunt KK, Babiera GV, Caudle AS, Black DM, Bedrosian I, Reyna C, Teshome M, Meric-Bernstam F, Hwang R. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Ann Surg Oncol. 2017 Mar; 24(3):652-659. PMID: 27822630.
      View in: PubMed
    28. Yao K, Belkora J, Bedrosian I, Rosenberg S, Sisco M, Barrera E, Kyrillios A, Tilburt J, Wang C, Rabbitt S, Pesce C, Simovic S, Winchester DJ, Sepucha K. Impact of an In-visit Decision Aid on Patient Knowledge about Contralateral Prophylactic Mastectomy: A Pilot Study. Ann Surg Oncol. 2017 Jan; 24(1):91-99. PMID: 27654108.
      View in: PubMed
    29. Davies KR, Brewster AM, Bedrosian I, Parker PA, Crosby MA, Peterson SK, Shen Y, Volk RJ, Cantor SB. Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033). Breast Cancer Res. 2016 09 20; 18(1):93. PMID: 27650678.
      View in: PubMed
    30. Menen RS, Ganesan N, Bevers T, Ying J, Coyne R, Lane D, Albarracin C, Bedrosian I. Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia. Ann Surg Oncol. 2017 Jan; 24(1):70-76. PMID: 27573525.
      View in: PubMed
    31. Carter SA, Lyons GR, Kuerer HM, Bassett RL, Oates S, Thompson A, Caudle AS, Mittendorf EA, Bedrosian I, Lucci A, DeSnyder SM, Babiera G, Yi M, Baumann DP, Clemens MW, Garvey PB, Hunt KK, Hwang RF. Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. Ann Surg Oncol. 2016 10; 23(10):3190-8. PMID: 27406093.
      View in: PubMed
    32. Yao K, Sisco M, Bedrosian I. Contralateral prophylactic mastectomy: current perspectives. Int J Womens Health. 2016; 8:213-23. PMID: 27382334.
      View in: PubMed
    33. Yao K, Belkora J, Sisco M, Rosenberg S, Bedrosian I, Liederbach E, Wang C. Survey of the Deficits in Surgeons' Knowledge of Contralateral Prophylactic Mastectomy. JAMA Surg. 2016 Apr; 151(4):391-3. PMID: 26606424.
      View in: PubMed
    34. Loveland-Jones C, Lin H, Shen Y, Bedrosian I, Shaitelman S, Kuerer H, Woodward W, Ueno N, Valero V, Babiera G. Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1218-25. PMID: 27209502.
      View in: PubMed
    35. McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2016; 11(3):e0151121. PMID: 26953790.
      View in: PubMed
    36. Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016 Apr 01; 34(10):1072-8. PMID: 26811528.
      View in: PubMed
    37. Parker PA, Peterson SK, Bedrosian I, Crosby MA, Shen Y, Black DM, Babiera G, Kuerer HM, Ying J, Dong W, Cantor SB, Brewster AM. Prospective Study of Surgical Decision-making Processes for Contralateral Prophylactic Mastectomy in Women With Breast Cancer. Ann Surg. 2016 Jan; 263(1):178-83. PMID: 25822675.
      View in: PubMed
    38. Nakhlis F, Gilmore L, Gelman R, Bedrosian I, Ludwig K, Hwang ES, Willey S, Hudis C, Iglehart JD, Lawler E, Ryabin NY, Golshan M, Schnitt SJ, King TA. Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). Ann Surg Oncol. 2016 Mar; 23(3):722-8. PMID: 26542585.
      View in: PubMed
    39. Shaitelman SF, Lin HY, Smith BD, Shen Y, Bedrosian I, Marsh GD, Bloom ES, Vicini FA, Buchholz TA, Babiera GV. Practical Implications of the Publication of Consensus Guidelines by the American Society for Radiation Oncology: Accelerated Partial Breast Irradiation and the National Cancer Data Base. Int J Radiat Oncol Biol Phys. 2016 Feb 01; 94(2):338-48. PMID: 26853342.
      View in: PubMed
    40. Swisher SK, Vila J, Tucker SL, Bedrosian I, Shaitelman SF, Litton JK, Smith BD, Caudle AS, Kuerer HM, Mittendorf EA. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Ann Surg Oncol. 2016 Mar; 23(3):749-56. PMID: 26511263.
      View in: PubMed
    41. McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851. PMID: 26325287.
      View in: PubMed
    42. Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer. 2015 Oct 01; 121(19):3422-7. PMID: 26280679.
      View in: PubMed
    43. Mittendorf EA, Bedrosian I, Hunt KK. Reply to L. Antolini et al. J Clin Oncol. 2015 Nov 20; 33(33):3978-9. PMID: 26282647.
      View in: PubMed
    44. Angelos P, Bedrosian I, Euhus DM, Herrmann VM, Katz SJ, Pusic A. Contralateral Prophylactic Mastectomy: Challenging Considerations for the Surgeon. Ann Surg Oncol. 2015 Oct; 22(10):3208-12. PMID: 26259752.
      View in: PubMed
    45. Lautner M, Lin H, Shen Y, Parker C, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. Disparities in the Use of Breast-Conserving Therapy Among Patients With Early-Stage Breast Cancer. JAMA Surg. 2015 Aug; 150(8):778-86. PMID: 26083835.
      View in: PubMed
    46. Bedrosian I, Xing Y, Abdel Rahman S, Allen L, Le-Petross H, Whitman GJ, Meric-Bernstam F, Hunt KK, Babiera GV, Cormier JN. A Cost Analysis of Preoperative Breast MRI Use for Patients with Invasive Lobular Cancer. Ann Surg Oncol. 2016 Jan; 23(1):23-9. PMID: 26156655.
      View in: PubMed
    47. Bhardwaj A, Ganesan N, Tachibana K, Rajapakshe K, Albarracin CT, Gunaratne PH, Coarfa C, Bedrosian I. Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling. PLoS One. 2015; 10(5):e0127678. PMID: 26000884.
      View in: PubMed
    48. Bedrosian I, Shen Y. Breast conserving therapy or mastectomy: a done deal or one worth returning to? J Comp Eff Res. 2015 May; 4(3):187-189. PMID: 25959556.
      View in: PubMed
    49. Bedrosian I, Yao K. Contralateral Prophylactic Mastectomy: Anxiety, Knowledge and Shared Decision Making. Ann Surg Oncol. 2015 Nov; 22(12):3767-8. PMID: 25920918.
      View in: PubMed
    50. Francis AM, Haugen CE, Grimes LM, Crow JR, Yi M, Mittendorf EA, Bedrosian I, Caudle AS, Babiera GV, Krishnamurthy S, Kuerer HM, Hunt KK. Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? Ann Surg Oncol. 2015 Dec; 22(13):4270-9. PMID: 25905585.
      View in: PubMed
    51. Mittendorf EA, Ballman KV, McCall LM, Yi M, Sahin AA, Bedrosian I, Hansen N, Gabram S, Hurd T, Giuliano AE, Hunt KK. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. J Clin Oncol. 2015 Apr 01; 33(10):1119-27. PMID: 25488970.
      View in: PubMed
    52. Karhade M, Hall C, Mishra P, Anderson A, Kuerer H, Bedrosian I, Krishnamurthy S, Lucci A. Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2014 Sep; 147(2):325-33. PMID: 25164970.
      View in: PubMed
    53. Bedrosian I, Yao K. Contralateral prophylactic mastectomy and survival: an ongoing challenge. Ann Surg Oncol. 2014 Oct; 21(11):3372-4. PMID: 25047481.
      View in: PubMed
    54. Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014 Jul 15; 20(14):3870-83. PMID: 24895461.
      View in: PubMed
    55. Rueth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, Babiera G. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J Clin Oncol. 2014 Jul 01; 32(19):2018-24. PMID: 24888808.
      View in: PubMed
    56. Caudle AS, Kuerer HM, Le-Petross HT, Yang W, Yi M, Bedrosian I, Krishnamurthy S, Fornage BD, Hunt KK, Mittendorf EA. Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol. 2014 Oct; 21(11):3440-7. PMID: 24859939.
      View in: PubMed
    57. Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez-MacGregor M, Woodward WA, Bedrosian I, Kuerer HM, Hunt KK. Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? Ann Surg Oncol. 2014 Aug; 21(8):2468-73. PMID: 24841348.
      View in: PubMed
    58. Deshmukh AA, Cantor SB, Crosby MA, Dong W, Shen Y, Bedrosian I, Peterson SK, Parker PA, Brewster AM. Cost of contralateral prophylactic mastectomy. Ann Surg Oncol. 2014 Sep; 21(9):2823-30. PMID: 24809301.
      View in: PubMed
    59. Bhardwaj A, Rosen D, Liu M, Liu Y, Hao Q, Ganesan N, Etzel CJ, Gullett A, Albarracin CT, Bedrosian I. Suppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis. PLoS One. 2014; 9(5):e97076. PMID: 24811059.
      View in: PubMed
    60. Mittendorf EA, Bedrosian I. Breast cancer biology: implications for local-regional therapy. Ann Surg Oncol. 2014 Sep; 21(9):2820-2. PMID: 24752612.
      View in: PubMed
    61. Haynes AB, Bloom ES, Bedrosian I, Kuerer HM, Hwang RF, Munsell MF, Chemaly RF, Graviss LS, Caudle AS, Hunt KK, Tereffe W, Shaitelman SF, Babiera GV. Timing of infectious complications following breast-conserving therapy with catheter-based accelerated partial breast irradiation. Ann Surg Oncol. 2014 Aug; 21(8):2512-6. PMID: 24736987.
      View in: PubMed
    62. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014 May; 25(5):1004-11. PMID: 24562447.
      View in: PubMed
    63. Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera GV. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer. 2014 May 01; 120(9):1319-28. PMID: 24510381.
      View in: PubMed
    64. Hwang ES, Bedrosian I. Patterns of breast magnetic resonance imaging use: an opportunity for data-driven resource allocation. JAMA Intern Med. 2014 Jan; 174(1):122-4. PMID: 24247170.
      View in: PubMed
    65. Advani PS, Ying J, Theriault R, Melhem-Bertrand A, Moulder S, Bedrosian I, Tereffe W, Black S, Pini TM, Brewster AM. Ethnic disparities in adherence to breast cancer survivorship surveillance care. Cancer. 2014 Mar 15; 120(6):894-900. PMID: 24258799.
      View in: PubMed
    66. Redis RS, Sieuwerts AM, Look MP, Tudoran O, Ivan C, Spizzo R, Zhang X, de Weerd V, Shimizu M, Ling H, Buiga R, Pop V, Irimie A, Fodde R, Bedrosian I, Martens JW, Foekens JA, Berindan-Neagoe I, Calin GA. CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget. 2013 Oct; 4(10):1748-62. PMID: 24077681.
      View in: PubMed
    67. Fitzsullivan E, Lari SA, Smith B, Caudle AS, Krishnamurthy S, Lucci A, Mittendorf EA, Babiera GV, Black DM, Wagner JL, Bedrosian I, Woodward W, Gainer SM, Hwang R, Meric-Bernstam F, Hunt KK, Kuerer HM. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013 Dec; 20(13):4103-12. PMID: 23975313.
      View in: PubMed
    68. Mittendorf EA, Buchholz TA, Tucker SL, Meric-Bernstam F, Kuerer HM, Gonzalez-Angulo AM, Bedrosian I, Babiera GV, Hoffman K, Yi M, Ross MI, Hortobagyi GN, Hunt KK. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg. 2013 Feb; 257(2):173-9. PMID: 23291658.
      View in: PubMed
    69. Lang JE, Tereffe W, Mitchell MP, Rao R, Feng L, Meric-Bernstam F, Bedrosian I, Kuerer HM, Hunt KK, Hortobagyi GN, Babiera GV. Primary tumor extirpation in breast cancer patients who present with stage IV disease is associated with improved survival. Ann Surg Oncol. 2013 Jun; 20(6):1893-9. PMID: 23306905.
      View in: PubMed
    70. Yi M, Kuerer HM, Mittendorf EA, Hwang RF, Caudle AS, Bedrosian I, Meric-Bernstam F, Wagner JL, Hunt KK. Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg. 2013 Jan; 216(1):105-13. PMID: 23122536.
      View in: PubMed
    71. Bedrosian I, Nelson H. The paradox of breast MRI: does finding occult disease make a difference? Bull Am Coll Surg. 2012 Oct; 97(10):57-9. PMID: 23115888.
      View in: PubMed
    72. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol. 2012 Sep; 36(9):1353-8. PMID: 22895267.
      View in: PubMed
    73. Alvarado R, Yi M, Le-Petross H, Gilcrease M, Mittendorf EA, Bedrosian I, Hwang RF, Caudle AS, Babiera GV, Akins JS, Kuerer HM, Hunt KK. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012 Oct; 19(10):3177-84. PMID: 22772869.
      View in: PubMed
    74. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM, Krishnamurthy S. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012 Jul; 13(7):688-95. PMID: 22677156.
      View in: PubMed
    75. Kong AL, Tereffe W, Hunt KK, Yi M, Kang T, Weatherspoon K, Mittendorf EA, Bedrosian I, Hwang RF, Babiera GV, Buchholz TA, Meric-Bernstam F. Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer. 2012 Dec 15; 118(24):6287-96. PMID: 22648744.
      View in: PubMed
    76. Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012 Nov; 19(12):3777-84. PMID: 22622473.
      View in: PubMed
    77. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012 May 23; 14(3):R83. PMID: 22621334.
      View in: PubMed
    78. Dominici LS, Mittendorf EA, Wang X, Liu J, Kuerer HM, Hunt KK, Brewster A, Babiera GV, Buchholz TA, Meric-Bernstam F, Bedrosian I. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res. 2012 May 23; 14(3):R82. PMID: 22621306.
      View in: PubMed
    79. Brewster AM, Bedrosian I, Parker PA, Dong W, Peterson SK, Cantor SB, Crosby M, Shen Y. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer. 2012 Nov 15; 118(22):5637-43. PMID: 22517269.
      View in: PubMed
    80. Peng G, Dai H, Zhang W, Hsieh HJ, Pan MR, Park YY, Tsai RY, Bedrosian I, Lee JS, Ira G, Lin SY. Human nuclease/helicase DNA2 alleviates replication stress by promoting DNA end resection. Cancer Res. 2012 Jun 01; 72(11):2802-13. PMID: 22491672.
      View in: PubMed
    81. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41. PMID: 22392043.
      View in: PubMed
    82. Yi M, Meric-Bernstam F, Kuerer HM, Mittendorf EA, Bedrosian I, Lucci A, Hwang RF, Crow JR, Luo S, Hunt KK. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012 Feb 20; 30(6):600-7. PMID: 22253459.
      View in: PubMed
    83. Wagner JL, Fearmonti R, Hunt KK, Hwang RF, Meric-Bernstam F, Kuerer HM, Bedrosian I, Crosby MA, Baumann DP, Ross MI, Feig BW, Krishnamurthy S, Hernandez M, Babiera GV. Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancer. Ann Surg Oncol. 2012 Apr; 19(4):1137-44. PMID: 21979111.
      View in: PubMed
    84. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep; 18(9):2407-12. PMID: 21327455.
      View in: PubMed
    85. Akay CL, Meric-Bernstam F, Hunt KK, Grubbs EG, Bedrosian I, Tucker SL, Kuerer HM, Hoffman KE, Babiera GV, Strom EA, Buchholz TA, Mittendorf EA. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012 Mar; 19(3):901-7. PMID: 21861223.
      View in: PubMed
    86. Wagner JL, Warneke CL, Mittendorf EA, Bedrosian I, Babiera GV, Kuerer HM, Hunt KK, Yang W, Sahin AA, Meric-Bernstam F. Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg. 2011 Jul; 254(1):119-24. PMID: 21494124.
      View in: PubMed
    87. Hall C, Krishnamurthy S, Lodhi A, Bhattacharyya A, Anderson A, Kuerer H, Bedrosian I, Singh B, Lucci A. Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer. 2012 Jan 15; 118(2):342-8. PMID: 21717428.
      View in: PubMed
    88. Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, Buzdar AU, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011 Mar; 253(3):572-9. PMID: 21209588.
      View in: PubMed
    89. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F, Bedrosian I, McGahren M, Agarwal R, Zhang F, Overgaard J, Alsner J, Neve RM, Kuo WL, Gray JW, Borresen-Dale AL, Mills GB. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics. 2010 Dec; 6(4):129-51. PMID: 21691416.
      View in: PubMed
    90. Valero V, Kong AL, Hunt KK, Yi M, Hwang RF, Meric-Bernstam F, Bedrosian I, Ross MI, Babiera GV, Litton JK, Mittendorf EA. Sentinel lymph node dissection is technically feasible in older breast cancer patients. Clin Breast Cancer. 2010 Dec 01; 10(6):477-82. PMID: 21147692.
      View in: PubMed
    91. Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, Bedrosian I, Rourke L, Hunt KK. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010 Oct; 17 Suppl 3:343-51. PMID: 20853057.
      View in: PubMed
    92. Kang T, Yi M, Hunt KK, Mittendorf EA, Babiera GV, Kuerer H, Bedrosian I, Hwang RF, Lucci A, Meric-Bernstam F. Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann Surg Oncol. 2010 Oct; 17 Suppl 3:280-5. PMID: 20853047.
      View in: PubMed
    93. Van Leeuwen BL, Rosenkranz KM, Feng LL, Bedrosian I, Hartmann K, Hunt KK, Kuerer HM, Ross M, Singletary SE, Babiera GV. The effect of under-treatment of breast cancer in women 80 years of age and older. Crit Rev Oncol Hematol. 2011 Sep; 79(3):315-20. PMID: 20655242.
      View in: PubMed
    94. Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34. PMID: 20647335.
      View in: PubMed
    95. Hall C, Krishnamurthy S, Lodhi A, Mosalpuria K, Kuerer HM, Meric-Bernstam F, Bedrosian I, Hunt KK, Lucci A. Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol. 2010 Dec; 17(12):3252-8. PMID: 20559739.
      View in: PubMed
    96. Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, Krishnamurthy S, Meric-Bernstam F. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer. 2010 Jun 01; 116(11):2543-8. PMID: 20336790.
      View in: PubMed
    97. Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010 Nov; 17(11):2899-908. PMID: 20443145.
      View in: PubMed
    98. Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010 Mar 17; 102(6):401-9. PMID: 20185801.
      View in: PubMed
    99. Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, Hwang RF, Kuerer HM, Ross MI, Meric-Bernstam F. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009 Oct; 250(4):558-66. PMID: 19730235.
      View in: PubMed
    100. Fearmonti RM, Batista LI, Meric-Bernstam F, Bedrosian I, Kuerer HM, Hunt KK, Eva Singletary S, Babiera GV. False negative rate of sentinel lymph node biopsy in multicentric and multifocal breast cancers may be higher in cases with large additive tumor burden. Breast J. 2009 Nov-Dec; 15(6):645-8. PMID: 19735388.
      View in: PubMed
    101. Fearmonti RM, Gayed IW, Kim E, Bedrosian I, Hunt KK, Meric-Bernstam F, Feig B, Ghonimi E, Warneke C, Babiera GV. Intra-individual comparison of lymphatic drainage patterns using subareolar and peritumoral isotope injection for breast cancer. Ann Surg Oncol. 2010 Jan; 17(1):220-7. PMID: 19680729.
      View in: PubMed
    102. Boughey JC, Goravanchi F, Parris RN, Kee SS, Kowalski AM, Frenzel JC, Bedrosian I, Meric-Bernstam F, Hunt KK, Ames FC, Kuerer HM, Lucci A. Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg. 2009 Nov; 198(5):720-5. PMID: 19427625.
      View in: PubMed
    103. Wagner J, Boughey JC, Garrett B, Babiera G, Kuerer H, Meric-Bernstam F, Singletary E, Hunt KK, Middleton LP, Bedrosian I. Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. Am J Surg. 2009 Sep; 198(3):387-91. PMID: 19362281.
      View in: PubMed
    104. Krishnamurthy S, Meric-Bernstam F, Lucci A, Hwang RF, Kuerer HM, Babiera G, Ames FC, Feig BW, Ross MI, Singletary E, Hunt KK, Bedrosian I. A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer. 2009 Apr 01; 115(7):1555-62. PMID: 19195040.
      View in: PubMed
    105. Boughey JC, Wagner J, Garrett BJ, Harker L, Middleton LP, Babiera GV, Meric-Bernstam F, Lucci A, Hunt KK, Bedrosian I. Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol. 2009 Jun; 16(6):1606-11. PMID: 19280264.
      View in: PubMed
    106. Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV, Hwang RF, Kuerer HM, Yang W, Hunt KK. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer. 2009 Mar 01; 115(5):962-71. PMID: 19172584.
      View in: PubMed
    107. Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I. Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat. 2009 Jun; 115(3):651-9. PMID: 19107593.
      View in: PubMed
    108. Reed VK, Woodward WA, Zhang L, Strom EA, Perkins GH, Tereffe W, Oh JL, Yu TK, Bedrosian I, Whitman GJ, Buchholz TA, Dong L. Automatic segmentation of whole breast using atlas approach and deformable image registration. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1493-500. PMID: 18804333.
      View in: PubMed
    109. Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Reuben J, Broglio K, Mosalpuria K, Lodhi A, Vincent L, Cristofanilli M. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat. 2009 Sep; 117(1):61-8. PMID: 18663571.
      View in: PubMed
    110. Yi M, Krishnamurthy S, Kuerer HM, Meric-Bernstam F, Bedrosian I, Ross MI, Ames FC, Lucci A, Hwang RF, Hunt KK. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg. 2008 Jul; 196(1):81-7. PMID: 18436181.
      View in: PubMed
    111. Badgwell BD, Giordano SH, Duan ZZ, Fang S, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera G. Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol. 2008 May 20; 26(15):2482-8. PMID: 18427152.
      View in: PubMed
    112. Rao R, Feng L, Kuerer HM, Singletary SE, Bedrosian I, Hunt KK, Ross MI, Hortobagyi GN, Feig BW, Ames FC, Babiera GV. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol. 2008 Jun; 15(6):1696-702. PMID: 18357493.
      View in: PubMed
    113. Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat. 2009 Feb; 113(3):501-7. PMID: 18327638.
      View in: PubMed
    114. Reed VK, Cavalcanti JL, Strom EA, Perkins GH, Oh JL, Tereffe W, Yu TK, Yeung H, Whitman GJ, Bedrosian I, Macapinlac HA, Buchholz TA, Woodward WA. Risk of subclinical micrometastatic disease in the supraclavicular nodal bed according to the anatomic distribution in patients with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2008 Jun 01; 71(2):435-40. PMID: 18164831.
      View in: PubMed
    115. Boughey JC, Cormier JN, Xing Y, Hunt KK, Meric-Bernstam F, Babiera GV, Ross MI, Kuerer HM, Singletary SE, Bedrosian I. Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. Cancer. 2007 Dec 01; 110(11):2542-50. PMID: 17932905.
      View in: PubMed
    116. Boughey JC, Middleton LP, Harker L, Garrett B, Fornage B, Hunt KK, Babiera GV, Dempsey P, Bedrosian I. Utility of ultrasound and fine-needle aspiration biopsy of the axilla in the assessment of invasive lobular carcinoma of the breast. Am J Surg. 2007 Oct; 194(4):450-5. PMID: 17826054.
      View in: PubMed
    117. Vo T, Xing Y, Meric-Bernstam F, Mirza N, Vlastos G, Symmans WF, Perkins GH, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Akins JS, Hunt KK. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007 Oct; 194(4):527-31. PMID: 17826073.
      View in: PubMed
    118. Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. Clin Cancer Res. 2007 Aug 15; 13(16):4800-6. PMID: 17699858.
      View in: PubMed
    119. Huang EH, Strom EA, Valero V, Fornage B, Perkins GH, Oh JL, Yu TK, Tereffe W, Woodward WA, Hunt KK, Meric-Bernstam F, Sahin AA, Bedrosian I, Hortobagyi GN, Buchholz TA. Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):490-6. PMID: 17236970.
      View in: PubMed
    120. Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Arun B, Hunt KK, Bedrosian I. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006 Oct 01; 107(7):1440-7. PMID: 16955504.
      View in: PubMed
    121. Vo TN, Meric-Bernstam F, Yi M, Buchholz TA, Ames FC, Kuerer HM, Bedrosian I, Hunt KK. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg. 2006 Oct; 192(4):552-5. PMID: 16978974.
      View in: PubMed
    122. Rosenkranz KM, Bedrosian I, Feng L, Hunt KK, Hartman K, Lucci A, Meric-Bernstam F, Kuerer HM, Singletary ES, Hwang R, Feig B, Ross M, Ames F, Babiera GV. Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. Am J Surg. 2006 Oct; 192(4):541-4. PMID: 16978971.
      View in: PubMed
    123. Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV, Singletary SE, Bedrosian I, Lucci A, Buzdar AU, Pusztai L, Kuerer HM. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006 Sep; 244(3):464-70. PMID: 16926572.
      View in: PubMed
    124. Boughey JC, Bedrosian I, Meric-Bernstam F, Ross MI, Kuerer HM, Akins JS, Giordano SH, Babiera GV, Ames FC, Hunt KK. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg. 2006 Oct; 203(4):475-80. PMID: 17000390.
      View in: PubMed
    125. Boughey JC, Ross MI, Babiera GV, Bedrosian I, Feig BW, Hwang RF, Kuerer HM, Hunt KK. Sentinel lymph node surgery in locally recurrent breast cancer. Clin Breast Cancer. 2006 Aug; 7(3):248-53. PMID: 16942642.
      View in: PubMed
    126. Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle. 2006 Aug; 5(15):1654-61. PMID: 16861913.
      View in: PubMed
    127. Bedrosian I, Giacco G, Pederson L, Rodriguez-Bigas MA, Feig B, Hunt KK, Ellis L, Curley SA, Vauthey JN, Delclos M, Crane CH, Janjan N, Skibber JM. Outcome after curative resection for locally recurrent rectal cancer. Dis Colon Rectum. 2006 Feb; 49(2):175-82. PMID: 16392024.
      View in: PubMed
    128. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, Liu J, Halder G, Mills GB. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A. 2005 Aug 30; 102(35):12519-24. PMID: 16116079.
      View in: PubMed
    129. Shen J, Hunt KK, Mirza NQ, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Ross MI, Ames FC, Feig BW, Singletary SE, Cristofanilli M, Meric-Bernstam F. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer. 2005 Aug 01; 104(3):479-90. PMID: 15968686.
      View in: PubMed
    130. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem. 2005 Apr 15; 280(15):15148-57. PMID: 15708847.
      View in: PubMed
    131. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene. 2004 Apr 08; 23(15):2648-57. PMID: 15007381.
      View in: PubMed
    132. Bedrosian I, Rodriguez-Bigas MA, Feig B, Hunt KK, Ellis L, Curley SA, Vauthey JN, Delclos M, Crane C, Janjan N, Skibber JM. Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma. J Gastrointest Surg. 2004 Jan; 8(1):56-62; discussion 62-3. PMID: 14746836.
      View in: PubMed
    133. Bedrosian I, Bedi D, Kuerer HM, Fornage BD, Harker L, Ross MI, Ames FC, Krishnamurthy S, Edeiken-Monroe BS, Meric F, Feig BW, Akins J, Singletary SE, Mirza NQ, Hunt KK. Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol. 2003 Nov; 10(9):1025-30. PMID: 14597440.
      View in: PubMed
    134. Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol. 2003 Oct 15; 21(20):3826-35. PMID: 14551301.
      View in: PubMed
    135. Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, Cheever MA, Cohen PA, Czerniecki BJ. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol. 2003 Sep 01; 171(5):2251-61. PMID: 12928369.
      View in: PubMed
    136. Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle. 2003 Sep-Oct; 2(5):461-6. PMID: 12963845.
      View in: PubMed
    137. Bedrosian I, Mick R, Orel SG, Schnall M, Reynolds C, Spitz FR, Callans LS, Buzby GP, Rosato EF, Fraker DL, Czerniecki BJ. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer. 2003 Aug 01; 98(3):468-73. PMID: 12879462.
      View in: PubMed
    138. Bedrosian I, Gershenwald JE. Surgical clinical trials in melanoma. Surg Clin North Am. 2003 Apr; 83(2):385-403. PMID: 12744615.
      View in: PubMed
    139. Rabinowitz I. Cyclin E in breast cancer. N Engl J Med. 2003 Mar 13; 348(11):1063-4; author reply 1063-4. PMID: 12638587.
      View in: PubMed
    140. Keyomarsi K, Tucker SL, Bedrosian I. Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med. 2003 Feb; 9(2):152. PMID: 12563321.
      View in: PubMed
    141. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002 Nov 14; 347(20):1566-75. PMID: 12432043.
      View in: PubMed
    142. Bedrosian I, Schlencker J, Spitz FR, Orel SG, Fraker DL, Callans LS, Schnall M, Reynolds C, Czerniecki BJ. Magnetic resonance imaging-guided biopsy of mammographically and clinically occult breast lesions. Ann Surg Oncol. 2002 Jun; 9(5):457-61. PMID: 12052756.
      View in: PubMed
    143. Bauer TW, Spitz FR, Callans LS, Alavi A, Mick R, Weinstein SP, Bedrosian I, Fraker DL, Bauer TL, Czerniecki BJ. Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann Surg Oncol. 2002 Mar; 9(2):169-76. PMID: 11888875.
      View in: PubMed
    144. Faries MB, Bedrosian I, Xu S, Koski G, Roros JG, Moise MA, Nguyen HQ, Engels FH, Cohen PA, Czerniecki BJ. Calcium signaling inhibits interleukin-12 production and activates CD83(+) dendritic cells that induce Th2 cell development. Blood. 2001 Oct 15; 98(8):2489-97. PMID: 11588047.
      View in: PubMed
    145. Wildemore JK, Schuchter L, Mick R, Synnestvedt M, Elenitsas R, Bedrosian I, Czerniecki BJ, Guerry D, Lessin SR, Elder DE, Bucky LP. Locally recurrent malignant melanoma characteristics and outcomes: a single-institution study. Ann Plast Surg. 2001 May; 46(5):488-94. PMID: 11352421.
      View in: PubMed
    146. Czerniecki BJ, Bedrosian I, Faries M, Alavi A. Revolutionary impact of lymphoscintigraphy and intraoperative sentinel node mapping in the clinical practice of oncology. Semin Nucl Med. 2001 Apr; 31(2):158-64. PMID: 11330786.
      View in: PubMed
    147. Czerniecki BJ, Cohen PA, Faries M, Xu S, Roros JG, Bedrosian I. Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines. Crit Rev Immunol. 2001; 21(1-3):157-78. PMID: 11642602.
      View in: PubMed
    148. Engels FH, Kreisel D, Faries MB, Bedrosian I, Koski GK, Cohen PA, Czerniecki BJ. Calcium ionophore activation of chronic myelogenous leukemia progenitor cells into dendritic cells is mediated by calcineurin phosphatase. Leuk Res. 2000 Oct; 24(10):795-804. PMID: 10996197.
      View in: PubMed
    149. Bedrosian I, Reynolds C, Mick R, Callans LS, Grant CS, Donohue JH, Farley DR, Heller R, Conant E, Orel SG, Lawton T, Fraker DL, Czerniecki BJ. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer. 2000 Jun 01; 88(11):2540-5. PMID: 10861431.
      View in: PubMed
    150. Bedrosian I, Faries MB, Guerry D, Elenitsas R, Schuchter L, Mick R, Spitz FR, Bucky LP, Alavi A, Elder DE, Fraker DL, Czerniecki BJ. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol. 2000 May; 7(4):262-7. PMID: 10819365.
      View in: PubMed
    151. Bedrosian I, Roros JG, Xu S, Nguyen HQ, Engels F, Faries MB, Koski GK, Cohen PA, Czerniecki BJ. Granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-12 synergize with calcium ionophore to enhance dendritic cell function. J Immunother. 2000 May-Jun; 23(3):311-20. PMID: 10838660.
      View in: PubMed
    152. Faries MB, Bedrosian I, Reynolds C, Nguyen HQ, Alavi A, Czerniecki BJ. Active macromolecule uptake by lymph node antigen-presenting cells: a novel mechanism in determining sentinel lymph node status. Ann Surg Oncol. 2000 Mar; 7(2):98-105. PMID: 10761787.
      View in: PubMed
    153. Engels FH, Koski GK, Bedrosian I, Xu S, Luger S, Nowell PC, Cohen PA, Czerniecki BJ. Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. Proc Natl Acad Sci U S A. 1999 Aug 31; 96(18):10332-7. PMID: 10468608.
      View in: PubMed
    154. Bedrosian I, Scheff AM, Mick R, Callans LS, Bucky LP, Spitz FR, Helsabeck C, Elder DE, Alavi A, Fraker DF, Czerniecki BJ. 99mTc-human serum albumin: an effective radiotracer for identifying sentinel lymph nodes in melanoma. J Nucl Med. 1999 Jul; 40(7):1143-8. PMID: 10405134.
      View in: PubMed
    155. Czerniecki BJ, Scheff AM, Callans LS, Spitz FR, Bedrosian I, Conant EF, Orel SG, Berlin J, Helsabeck C, Fraker DL, Reynolds C. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer. 1999 Mar 01; 85(5):1098-103. PMID: 10091794.
      View in: PubMed
    156. Clark BD, Bedrosian I, Schindler R, Cominelli F, Cannon JG, Shaw AR, Dinarello CA. Detection of interleukin 1 alpha and 1 beta in rabbit tissues during endotoxemia using sensitive radioimmunoassays. J Appl Physiol (1985). 1991 Dec; 71(6):2412-8. PMID: 1778940.
      View in: PubMed
    157. Bedrosian I, Sofia RD, Wolff SM, Dinarello CA. Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine. 1991 Nov; 3(6):568-75. PMID: 1790304.
      View in: PubMed
    158. Predicting the Extent of Nodal Disease in Early-Stage Breast Cancer. Annals of Surgical Oncology.
    159. 4-1 Which Cyclin E Prevails as Prognostic Marker for Breast Cancer? Results from a Retrospective Study Involving 635 Lymph Node-Negative Breast Cancer Patients. Breast Diseases. 17:332-333.
    160. Association of cyclin D1 genotype with breast cancer risk and survival. Breast Diseases. 16:251-252.
    161. Reply to K.J. Van Zee et al. Journal of Clinical Oncology. 30:3144-3145.
    162. Long-term follow-up study of a prospective multicenter sentinel node trial. Breast Diseases. 22:392-393.
    163. Breast cancer. 479-507.
    164. Impact of breast cancer subtypes on local-regional outcomes. Current Breast Cancer Reports. 2:107-113.
    165. Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer. Annals of Surgical Oncology. 1-9.
    166. Tissue microarray analyses of GI/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin DI is associated with local recurrence. Breast Diseases. 15:313-314.
    167. Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy. Annals of Surgical Oncology. 23:722-728.
    168. In reply. Journal of Clinical Oncology. 27:641-642.
    169. A Cost Analysis of Preoperative Breast MRI Use for Patients with Invasive Lobular Cancer. Annals of Surgical Oncology.
    170. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Breast Diseases. 15:292-293.
    171. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Annals of Surgical Oncology. 23:749-756.
    172. Outcomes of contralateral prophylactic mastectomy in relation to familial history. Breast Cancer Research. 18.
    173. Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia. Annals of Surgical Oncology. 1-7.
    174. Prospective Study of Surgical Decision-making Processes for Contralateral Prophylactic Mastectomy in Women With Breast Cancer. Annals of Surgery.
    175. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Annals of Surgical Oncology. 1-8.
    176. Ability to generate patient-derived Breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes. PLoS One. 10.
    177. Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer. International Journal of Radiation Oncology Biology Physics.
    178. Surveillance of women with a personal history of breast cancer by tumour subtype. Clinical Radiology.
    179. Current Multidisciplinary Management of High-Risk Breast Lesions. Current Breast Cancer Reports. 7:81-89.
    180. Response. Journal of the National Cancer Institute. 102:1372-1373.
    181. Erratum. PLoS One. 11.
    182. Contralateral Prophylactic Mastectomy. Annals of Surgical Oncology. 22:3208-3212.
    183. Annexin A1 preferentially predicts poor prognosis of basal-like breast cancer patients by activating mTOR-S6 signaling. PLoS One. 10.
    184. Improved axillary evaluation following neoadjuvant therapy for patientswith node-positive breast cancer using selective evaluation of clipped nodes. Journal of Clinical Oncology. 34:1072-1078.
    185. The prognostic implication of the basal-like (cyclin Ehigh/ p27low/p53+glomeruloid-microvascular-proliferation +) phenotype of BRCA1-related breast cancer. Breast Diseases. 15:387-388.
    186. Breast conserving therapy or mastectomy. Journal of Comparative Effectiveness Research. 4:187-189.
    187. Impact of an In-visit Decision Aid on Patient Knowledge about Contralateral Prophylactic Mastectomy. Annals of Surgical Oncology. 1-9.
    188. 2-24 Pathologic Correlates of False Positive Breast Magnetic Resonance Imaging Findings. Breast Diseases. 17:158.
    189. Contralateral prophylactic mastectomy. International Journal of Women's Health. 8:213-223.
    BEDROSIAN's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description